Adagio Therapeutics, Inc. (ADGI)
|Net Income (ttm)||-12.37M|
|Day's Range||33.80 - 39.31|
|52-Week Range||17.38 - 78.82|
Adagio Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. Our lead product candidate, ADG20, is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent. We have completed enrollment in our first-in-human Phase 1 clinical trial of ADG20. We are also conducting two separate Phase 2/3 clinical trials: ... [Read more...]
It's quite possible.
On Tuesday, Adagio Therapeutics Inc. (NASDAQ:ADGI) shares skyrocketed by more than 35% before declining for a mid-day net gain of about 4.5%. The rally was fueled by social media chatter, which saw trad...
Adagio Therapeutics (ADGI) stock is rising higher on Tuesday as investors on social media can't stop talking about the company. The post ADGI Stock: The Social Media Chatter That Has Adagio Therapeutics...
Adagio Therapeutics CEO: We see a role in the treatment of Covid, as well as prevention
Tillman Gerngross, Adagio Therapeutics CEO, joins 'The Exchange' to discuss how his company's antibody drug was developed and its effectiveness in fighting Covid variants.
Adagio Therapeutics Inc (NASDAQ: ADGI) was up more than 75% on Monday after the biotech firm said Omicron was unlikely to be more resistant against its investigational monoclonal antibody, ADG20, despit...
Shares of ADGI stock are soaring higher by 80% after the company stated that its ADG-20 antibody is effective against the omicron variant. The post ADGI Stock Soars as Analysts Lock On to Its Omicron-Fi...
The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a handful of biopharma stocks, according to a Morgan Stanley an...
Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Es...
Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Co...
WALTHAM, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of anti...
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID-19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expec...
WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of anti...
Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new in vitro data demonstrating retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the new...
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Kno...
Data to be presented at the 2021 ISIRV-WHO Virtual Conference Data to be presented at the 2021 ISIRV-WHO Virtual Conference
Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new data from its COVID-19 antibody program. Related Link: Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial.
Adagio Therapeutics to Participate in the Guggenheim 2nd Annual Vaccines & Infectious Day Conference
WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of an...
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021...
New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021
Adagio Therapeutics Inc (NASDAQ: ADGI) announced that the independent data monitoring committee (IDMC) has recommended expanding the ADG20 EVADE Phase 2/3 trial for COVID-19. The IDMC has supported the ...
Find out what these industry favorites are doing to impress investors.
WALTHAM, Mass.--(BUSINESS WIRE)--Adagio Therapeutics Announces Pricing of Initial Public Offering